Human Stem Cell Differentiation to Oligodendrocytes

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods fail to produce fully differentiated and mature oligodendrocytes from human embryonic stem cells, which are essential for treating central nervous system (CNS) disorders associated with demyelination, as previous attempts have yielded only partial success and procedures successful with murine ES cells cannot be extrapolated to human ES cells.

Innovation Solution

A method involving the growth of human stem cells in the presence of retinoic acid to form neurospheres, followed by contact with an agent capable of down-regulating Bone Morphogenic Protein activity, such as noggin, to induce differentiation into oligodendrocytes, allowing for the generation of mature and expandable oligodendrocyte precursors that can myelinate in vitro and in vivo.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Manufacturing precision

If human ES cells are cultured under standard differentiation conditions, then neural progenitor cells are formed, but fully differentiated and mature oligodendrocytes are not produced

Engineering Contradiction:

Improvedifferentiation completenessVSAvoidoligodendrocyte yield

Core Design Contradiction:

Manufacturing precisionVSProductivity

Solution Approach 1:

The patent applies parameter changes by systematically modifying culture conditions including adding specific growth factors (BMP4, FGF2, TGFβ1), adjusting retinoic acid concentration and timing, and controlling serum replacement composition to achieve complete oligodendrocyte differentiation from human ES cells

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent employs preliminary action by first forming neural progenitor cells and neuroepithelial structures before inducing oligodendrocyte differentiation, following a staged differentiation protocol that prepares the cells in sequential steps to achieve mature oligodendrocytes

Inventive Principle:

Principle #10Preliminary action

2Adaptability or versatility

If murine ES cell differentiation procedures are applied to human ES cells, then some oligodendrocyte production is achieved, but the procedure is not fully effective

Engineering Contradiction:

Improveprocedure transferabilityVSAvoiddifferentiation success rate

Core Design Contradiction:

Adaptability or versatilityVSReliability

Solution Approach 1:

The patent applies local quality by identifying species-specific requirements in the differentiation protocol, tailoring growth factor combinations, timing, and culture conditions specifically for human ES cells rather than using generic murine protocols, thereby achieving reliable human oligodendrocyte production

Inventive Principle:

Principle #3Local quality

3Quantity of substance

If human ES cells are expanded in large scale cultures, then sufficient cell numbers are obtained, but the ability to produce oligodendrocytes is lost

Engineering Contradiction:

Improvecell quantityVSAvoiddifferentiation capacity

Core Design Contradiction:

Quantity of substanceVSManufacturing precision

Solution Approach 1:

The patent applies preliminary action by maintaining undifferentiated human ES cells in expanded cultures, then initiating the differentiation protocol at the appropriate stage to generate oligodendrocytes from the expanded cell population, thus preserving differentiation capacity while achieving scale

Inventive Principle:

Principle #10Preliminary action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach successfully generates mature oligodendrocytes that can myelinate in vivo, providing a therapeutic solution for CNS disorders by enabling the production of fully differentiated and functional oligodendrocytes from human ES cells, overcoming previous limitations in human ES cell differentiation.

Implementation Method 1

growing human stem cells under conditions which induce differentiation of the human stem cells into the neural and glial cells, the conditions comprising the presence of retinoic acid

Methodology Applied

Scientific EffectDifferentiation induction:

Implementation Method 2

contacting the neurospheres with an agent capable of down-regulating Bone Morphogenic Protein activity, such as noggin

Methodology Applied

Scientific EffectProtein activity down-regulation:

Implementation Method 3

growing human stem cells in the presence of retinoic acid, under conditions which allow formation of neurospheres

Methodology Applied

Scientific EffectSphere formation:

Implementation Method 4

Oligodendrocytes extend as many as 50 processes which wrap around axons to form myelin sheaths

Methodology Applied

Scientific EffectMyelination:

Data Source

PatentUS11406670B2Methods of generating glial and neuronal cells and use of same for the treatment of medical conditions of the CNS

Publication Date: 2022.08.09 YEDA RES & DEV CO LTD

AI summary

A method of generating neural and glial cells is provided. The method comprising growing human stem cells under conditions which induce differentiation of said human stem cells into the neural and glial cells, said conditions comprising the presence of retinoic acid and an agent capable of down-regulating Bone Morphogenic Protein activity.